Ajanta Pharma has launched Memantine Hydrochloride Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Memantine Hydrochloride is an anti-dementia drug and is a bioequivalent generic version of Namenda. The company has launched it in 2 strengths 5mg & 10mg tablets to address different levels of treatment.
Memantine Hydrochloride Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. Till date, the United States Food & Drug Administration (USFDA) has granted 10 final approvals and 2 tentative approvals to Ajanta Pharma for its Abbreviated New Drug Application (ANDA). Additional 14 ANDAs are pending approval from the USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: